Treatment of comorbid COPD and cardiovascular disease requires careful consideration of drug interactions and adverse effects on the respective comorbid conditions.
Requires cautious drug selection in comorbid COPD-CVD; leaves open need for dedicated trials on safe combinations.
This review provided recent information about treatment of patients with comorbid respiratory and cardiovascular disease. Cardiorespiratory comorbidity is associated with cross"deterioration of the disease course given similar pathogenic components. This could decrease effects of treatment, worsen prognosis and actually requires new approaches to diagnosis and therapy. While choosing the treatment strategy for a patient with comorbid chronic obstructive pulmonary disease (COPD) and cardiovascular disease, a physician should be aware of the pooled risk of adverse events. Some agents widely used for treatment of cardiovascular diseases could worsen the course of COPD and, vice versa, bronchodilators that are the essential component of therapy of chronic obstructive bronchitis could adversely affect the cardiovascular system. Therefore, medication choice could be significantly limited due to comorbidity.
No takes yet. Share an insight, caveat, or question.
Ватутин et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: